HC Wainwright Reaffirms Buy Rating for Oruka Therapeutics (NASDAQ:ORKA)

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $120.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 93.77% from the stock’s previous close.

Several other research analysts also recently weighed in on ORKA. Wall Street Zen upgraded Oruka Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 16th. Leerink Partners set a $120.00 target price on Oruka Therapeutics in a research note on Thursday, April 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, April 21st. UBS Group lifted their target price on shares of Oruka Therapeutics from $75.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Finally, Barclays lifted their target price on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a report on Monday, April 27th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $120.80.

Oruka Therapeutics Stock Performance

Shares of Oruka Therapeutics stock opened at $61.93 on Monday. Oruka Therapeutics has a 1 year low of $9.40 and a 1 year high of $91.00. The company has a market capitalization of $3.73 billion, a P/E ratio of -31.92 and a beta of -0.20. The company’s fifty day moving average is $55.17 and its two-hundred day moving average is $39.42.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.04. As a group, equities analysts expect that Oruka Therapeutics will post -2.15 earnings per share for the current year.

Insider Activity at Oruka Therapeutics

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of the business’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $61.85, for a total transaction of $432,950.00. Following the sale, the insider directly owned 33,377 shares in the company, valued at approximately $2,064,367.45. The trade was a 17.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the business’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $41.30, for a total transaction of $71,407.70. Following the sale, the chief executive officer owned 927,309 shares in the company, valued at $38,297,861.70. The trade was a 0.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 30,765 shares of company stock valued at $1,522,695 over the last three months. Insiders own 23.49% of the company’s stock.

Institutional Trading of Oruka Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Fairmount Funds Management LLC lifted its stake in shares of Oruka Therapeutics by 9.9% in the third quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock valued at $71,252,000 after purchasing an additional 333,340 shares during the period. Secure Asset Management LLC acquired a new stake in shares of Oruka Therapeutics in the fourth quarter valued at about $2,475,000. Avoro Capital Advisors LLC acquired a new stake in shares of Oruka Therapeutics in the third quarter valued at about $25,640,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new stake in shares of Oruka Therapeutics in the third quarter valued at about $296,000. Finally, Commodore Capital LP lifted its stake in shares of Oruka Therapeutics by 23.5% in the third quarter. Commodore Capital LP now owns 1,753,054 shares of the company’s stock valued at $33,711,000 after purchasing an additional 333,340 shares during the period. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.